Interview with Bertrand Baron, CEO, Sanofi Mexico
Sanofi acquired Kendrick in 2009. Obviously the thinking behind it was to diversify your products into pure generics, but what were the expectations for the move? We have a diversified…
Address: Av. Universidad N° 1738
Col. Coyoacán
04000 México, D.F.
Tel: 54 84 44 00
Web: http://www.sanofi.com.mx/l/mx/sp/index.jsp
Present in more than 100 countries, with around 11,000 scientists, Sanofi has around 100,000 employees working to improve health and wellbeing. Sanofi’s global headquarters are in Paris, France. Sanofi in Mexico counts on nine major therapeutic areas and its own line of generic medicines.
Sanofi focuses its activities on 9 major therapeutic areas: Cardiovascular, Thrombosis, Diabetes, Oncology, Central Nervous System, Internal Medicine, Vaccines, OTC and Personal Health Care
Sanofi acquired Kendrick in 2009. Obviously the thinking behind it was to diversify your products into pure generics, but what were the expectations for the move? We have a diversified…
Luisa Gutierrez, CEO at Medisi, explains the importance of helping get fast registration for high quality medtech products registrations and explains Medisi’s integral solutions for both the regulation and distribution…
Xavier Rams, General Director at Ferrer Mexico, explains the importance of aligning corporate strategy to public healthcare goals in order to succeed in the dynamic Mexican environment and showcases the…
Zurich Pharma was created with the vision of becoming a leader in the oncology segment at the international level. General manager and founder, Orlando Silva Fernandéz, discusses how state-of-the-art technology…
President and CEO of Grupo ENESA, Jaime Chico Pardo breaks down the private capital fund’s core investment pillars—centered on active management and driving long-term value—while elaborating on the flourishing opportunities…
Roberto Tapia-Conyer, General Director at the Carlos Slim Foundation, explains the unique position of the Foundation to develop and introduce innovation that could create breakthroughs in the National Healthcare System…
Cecilia Calderón, general director at Vigpharma, highlights how the national pharmacovigilance and technovigilance regulations have been evolving during the last five years as well as showcasing the added value of…
Joel Osorio, CEO & Founder Alejandro De La Parra, Co-Founder & Chief Operating Officer Alexa Jeppi, Co-Founder, RegenerAge Beauty & Health Ira Pastor, Board Member …
Representatives of Olivares, one of the leading law firms in Mexico, explain the evolving status of cannabis and narcotics for medicinal use in the country. A new Bill authorizing the…
M.S. Nagendra, Director General at Zydus Pharmaceuticals Mexico, explains the company’s unique business model, combining both branded generics and highly innovative medicines, while showcasing the strategic relevance of the Mexican…
Paulo de Resende, CEO of Laboratorios Grin-Lupin in Mexico, describes the current state of the Mexican pharmaceutical market and explains how the acquisition of Laboratorios Grin will help increase Lupin’s…
Enrique Carballido, general manager Mexico and Latin South America at Bio-Rad, showcases Bio-Rad’s offering in both diagnostics and life sciences and the crucial role of the entire industry in helping…
The founder and managing partner of the LatAm-based consultancy Oriundo, Paul Doulton discusses the company’s unique value offering—comprising both industry veterans and global associates to propel business development—while highlighting Mexico…
See our Cookie Privacy Policy Here
